Immune rsponses and potection against eperimental callenge after vccination of bson with bucella abortus srain RB51 or RB51 overexpressing speroxide dsmutase and gycosyltransferase gnes

Clinical and Vaccine Immunology

Volumn 16, Issue 4, 2009, Pages 535-540

  Olsen, S C ^a   Boyle, S M ^b   Schurig, G G ^b   Sriranganathan, N N ^b  

^a NATIONAL ANIMAL DISEASE CENTER   (United States)

^b VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUCELLA VACCINE; BRUCELLA VACCINE RB51; GAMMA INTERFERON; GLYCOSYLTRANSFERASE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; LIVE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BRUCELLA ABORTUS; BRUCELLA ABORTUS RB51; BRUCELLOSIS; BUFFALO; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; GENE; GENE OVEREXPRESSION; IMMUNE RESPONSE; INTERFERON PRODUCTION; LYMPHATIC DRAINAGE; NONHUMAN; PRIORITY JOURNAL; SODC GENE; STRAIN IDENTIFICATION; VACCINATION; WBOA GENE; ANIMAL; ANIMAL DISEASE; BIOSYNTHESIS; BLOOD; FEMALE; GENETICS; IMMUNOLOGY; LYMPH NODE; MICROBIOLOGY; MONONUCLEAR CELL; PREGNANCY; SEPTIC ABORTION; UNITED STATES;

ABORTION, SEPTIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BISON; BRUCELLA ABORTUS; BRUCELLA VACCINE; BRUCELLOSIS; FEMALE; GLYCOSYLTRANSFERASES; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; PREGNANCY; SUPEROXIDE DISMUTASE; UNITED STATES; VACCINES, ATTENUATED;

EID: 64549096387     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00419-08     Document Type: Article

References (15)

1. Alton, G. G., L. M. Jones, R. D. Angus, and J. M. Verger. 1988. Bacteriological methods serological methods, p. 17-136. In Techniques for the brucellosis laboratory. Institut National de la Recherche Agronomique, Paris, France.
2. Bricker, B. J., L. B. Tabatabai, B. A. Judge, B. L. Deyoe, and J. E. Mayfield. 1990. Cloning and expression and occurrence of the Brucella Cu-Zn superoxide dismutase. Infect. Immun. 58:2935-2939.
3. Cheville, N. F., A. E. Jensen, S. M. Halling, F. M. Tatum, D. C. Morfitt, S. G. Hennager, W. M. Frerichs, and G. Schurig. 1992. Bacterial survival, lymph node changes and immunologic responses of cattle vaccinated with standard and mutant strains of Brucella abortus. Am. J. Vet. Res. 53:1881-1888.
4. Cheville, N. F., S. C. Olsen, A. E. Jensen, M. G. Stevens, and M. V. Palmer. 1996. Effects of age at vaccination on efficacy of Brucella abortus strain RB51 to protect cattle against brucellosis. Am. J. Vet. Res. 57:1153-1156.
5. Davis, D. S. 1993. Summary ofbison/brucellosis research conducted at Texas A&M University 1985-1993, p. 347-361. In R. E. Walker (ed.), Proceedings of North American Public Bison Herds Symposium. National Bison Association, Denver, CO.
6. Kreeger, T. J., W. E. Cook, W. H. Edwards, P. H. Elzer, and S. C. Olsen. 2002. Brucella abortus strain RB51 vaccination in elk. II. Failure of high dosage to prevent abortion. J. Wildl. Dis. 38:27-31.
7. Lee, L.-K., S. C. Olsen, and C. A. Bolin. 2001. Effects of exogenous recombinant interleukin-12 on immune responses and protection against Brucella abortus in a murine model. Can. J. Vet. Res. 65:223-228.
8. Olsen, S. C., S. J. Fach, M. V. Palmer, R. E. Sacco, W. C. Stoffregen, and W. R. Waters. 2006. Immune responses of elk to initial and booster vaccinations with Brucella abortus strain RB51 or 19. Clin. Vaccine Immunol. 13:1098-1103.
9. Olsen, S. C., A. E. Jensen, W. C. Stoffregen, and M. V. Palmer. 2003. Efficacy of calfhood vaccination with Brucella abortus strain RB51 in protecting bison against brucellosis. Res. Vet. Sci. 74:17-22.
10. Olsen, S. C., T. J. Kreeger, and W. Schultz. 2002. Immune responses of bison to ballistic or hand vaccination with Brucella abortus strain RB51. J. Wildl. Dis. 38:738-745.
11. Sriranganathan, N., S. M. Boyle, G. G. Schurig, and H. Misra. 1990. Super-oxide dismutases of virulent and avirulent strains of Brucella abortus. Vet. Microbiol. 26:359-366.
12. Vemulapalli, R., A. Contreras, N. Sanakkayala, N. Sriranganathan, S. M. Boyle, and G. G. Schurig. 2004. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice. Vet. Microbiol. 102:237-245.
13. Vemulapalli, R., Y. He, L. S. Buccolo, S. M. Boyle, N. Sriranganathan, and G. G. Schurig. 2000. Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough phenotype and attenuation. Infect. Immun. 68:3927-3932.
14. Vemulapalli, R., Y. He, S. Cravero, N. Sriranganathan, S. M. Boyle, and G. G. Schurig. 2000. Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. Infect. Immun. 68:3286-3289.
15. Vemulapalli, R., J. R. McQuiston, G. G. Schurig, N. Sriranganathan, S. M. Halling, and S. M. Boyle. 1999. Identification of an IS711 element interrupting the wboA gene of Brucella abortus vaccine strain RB51 and a PCR assay to distinguish strain RB51 from other Brucella species and strains. Clin. Diagn. Lab. Immunol. 6:760-764.